Dongmei Ji

7PUBLICATIONS
52CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)GlycoconjugatesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 22, 2026
Durable Intracranial Response to Sacituzumab Tirumotecan in HER2-Negative Salivary Duct Carcinoma With High TROP2 Expression: A Case Report.

|Aug 11, 2026
Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression.

|Mar 30, 2026
LM-101, an Anti-SIRPα Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I Trial.

Jun Cai, Baitian Zhao, Dongmei Ji

|Nov 13, 2023
Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial.

Xiaomin Ou, Ruiping Zhai, Wenjun Wei

|Jun 29, 2022
Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer.

Jian Zhang, Dongmei Ji, Weina Shen

|Nov 30, 2021
First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study.

Jian Zhang, Dongmei Ji, Li Cai

Pageof 2

Frequent Collaborators

3 joint publications

Xin Liu

2 joint publications

Guang-Liang Chen

2 joint publications

Yulong Wang

2 joint publications

Weina Shen